Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

AMGNAmgenRunning, no new patients

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Relapsed/Refractory Small Cell Lung Cancer

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 3 insiders sold shares within a month

    Since Aug 13, 2026 · was worth 5, fading over time

    +1.9
Worry score2

Score over time

Stage
Phase 2
Patients
222 (final count)
Started
Dec 1, 2021
Main results expected
Dec 30, 2027
Fully finished
Dec 30, 2027
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator

    Measured over: Up to a maximum of 61 months

  • Part 1 and Part 3 Only: Number of Participants who Experience One or More Treatment-emergent Adverse Events

    Measured over: Up to a maximum of 61 months

  • Part 1 Only: Serum Concentrations of Tarlatamab

    Measured over: Up to a maximum of 24 months

  • Part 1 and Part 2 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR)

    Measured over: Up to a maximum of 61 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT05060016 · record last updated 2026-07-22 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05060016) ↗